How Your Brain Controls Bone Health Through the Sympathetic Nervous System
A comprehensive review reveals the brain-bone axis as a critical regulator of skeletal aging, opening new therapeutic targets for osteoporosis and arthritis.
Summary
This 2025 review in Bone Research examines the brain-bone axis (BBA), a bidirectional communication network linking the sympathetic nervous system (SNS) to skeletal metabolism. The SNS regulates bone through neurotransmitters including norepinephrine, dopamine, neuropeptide Y, and leptin, each acting on receptors expressed by osteoblasts, osteoclasts, chondrocytes, and mesenchymal stem cells. SNS overactivation suppresses bone formation and promotes resorption, contributing to osteoporosis, osteoarthritis, and intervertebral disc degeneration. Conversely, bone-derived factors like osteocalcin and lipocalin-2 cross the blood-brain barrier to influence neurological function. The authors propose neuro-centric therapeutic strategies targeting SNS signaling pathways as a novel approach to managing age-related skeletal disease.
Detailed Summary
With the global population aging rapidly—projected to reach 2.1 billion people over age 60 by mid-century—age-related skeletal disorders represent a mounting public health crisis. Osteoarthritis currently affects roughly 595 million people worldwide, and osteoporotic fractures are expected to reach 3.3 million annually by 2030 with associated costs exceeding €47 billion. This landscape has driven researchers to look beyond conventional orthopedic biology toward neurological regulation of bone metabolism.
This comprehensive review, published in Bone Research (2025), systematically examines the brain-bone axis (BBA)—a bidirectional neuro-skeletal communication network in which the sympathetic nervous system (SNS) serves as the central regulatory hub. Sympathetic fibers innervate the periosteum, bone marrow, and nutrient canals of long bones, releasing primarily norepinephrine (NE) from postganglionic terminals. NE binds to β2-adrenergic receptors (β2-ARs) on osteoblasts, activating the cAMP/PKA/CREB pathway to inhibit osteogenic differentiation, while simultaneously upregulating RANKL via ATF4 phosphorylation to promote osteoclast formation and bone resorption. Cholinergic sympathetic fibers exert complementary anabolic effects on bone formation through regulation of the bone marrow microenvironment.
Beyond NE, the review details the roles of dopamine, neuropeptide Y (NPY), and leptin. Dopaminergic signaling dysregulation promotes inflammatory cytokine release and cartilage degradation in osteoarthritis. NPY inhibits osteogenesis and accelerates extracellular matrix degradation. Leptin activates the hypothalamic-sympathetic pathway centrally to suppress bone formation via NE release, while also modulating bone metabolism directly through peripheral receptors. These molecules form an integrated regulatory network whose imbalance is mechanistically linked to osteoporosis, osteoarthritis, and intervertebral disc degeneration.
Equally important is the reverse signaling direction: bone-derived osteokines including osteocalcin (OCN), lipocalin-2 (LCN-2), osteopontin (OPN), and RANKL can cross the blood-brain barrier to influence neurological function. OCN modulates hippocampal and brainstem activity, enhances catecholamine synthesis, and has been shown to promote dopaminergic neuron survival via the AKT/GSK3β pathway in Parkinson's disease models. LCN-2 contributes to neuroinflammation in Alzheimer's and Parkinson's diseases, while OPN supports myelination and macrophage activity relevant to neuronal repair.
The authors propose neuro-centric therapeutic strategies targeting SNS components—including β-AR antagonists, dopaminergic modulators, and NPY pathway inhibitors—as novel approaches to treating skeletal disease. While the review synthesizes a compelling mechanistic framework, it is largely based on animal and in vitro studies, and the translation of these findings to human clinical interventions remains an important frontier requiring rigorous investigation.
Key Findings
- SNS-released norepinephrine activates β2-adrenergic receptors on osteoblasts, suppressing bone formation and promoting resorption via RANKL upregulation.
- Dopamine dysregulation in the brain-bone axis accelerates cartilage degradation and inflammatory cytokine release in osteoarthritis.
- Neuropeptide Y inhibits osteogenesis and promotes extracellular matrix degradation, contributing to osteoarthritis progression.
- Bone-derived osteocalcin crosses the blood-brain barrier and supports dopaminergic neuron survival via AKT/GSK3β signaling.
- Leptin activates the hypothalamic-sympathetic pathway to suppress bone formation, linking metabolic and skeletal regulation.
Methodology
This is a comprehensive narrative review article integrating evidence from animal studies, in vitro experiments, and human epidemiological data. The authors synthesize findings across molecular biology, neuroanatomy, and clinical orthopedics to construct a mechanistic framework for SNS regulation of skeletal homeostasis. No original experimental data were generated; conclusions are drawn from synthesis of existing literature.
Study Limitations
The majority of mechanistic evidence cited derives from murine models and cell culture systems, limiting direct extrapolation to human physiology and disease. The review does not include systematic literature search methodology, introducing potential selection bias in the studies discussed. Clinical trial data directly testing neuro-centric skeletal interventions remain sparse, and the complex crosstalk among neurotransmitter systems makes targeted therapeutic development challenging.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: